ClinicalTrials.gg
CompletedNCT04153981Updated Feb 15, 2024Results posted

A Study of Insulin Glargine (LY2963016) in Adult Participants With Type 2 Diabetes in India

A Phase 4 interventional study of Insulin Glargine in Type 2 Diabetes Mellitus, sponsored by Eli Lilly and Company. Completed at 11 sites in India. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-02-15.

Sponsored by Eli Lilly and Company · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
304
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 — 4 open to participants now, 6 under way, 1 of them phase 3. Insulin Glargine · Diabetes Mellitus, Type 2.

Enrollment
77th of 175
304 · median 253
Started
2019
with 5 others
Phase 4
103 of 176
2 open now
Registered
154th of 176
by date
Lead sponsor
15 of 176
Eli Lilly and Company

Among the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, this one is the 77th largest by enrollment of the 175 interventional ones that give a count, is one of 6 that started in 2019, is one of 103 in phase 4, and was the 154th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

4 of the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About Insulin Glargine

Insulin Glargine: first FDA approval 2000 (LANTUS SOLOSTAR), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The reason for this study is to see if insulin glargine is safe in participants with type 2 diabetes mellitus (T2DM) in India.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have T2DM based on the disease diagnostic criteria from the World Health Organization (WHO) classification for at least 6 months before screening.
  • Have been receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) or ≥2 oral antihyperglycemic medication (OAMs) at stable doses for 90 days prior to screening.
  • Have an level ≥7.0% and \<11.0%.
  • Have never been treated with insulins except for short term treatment of acute conditions up to a maximum of 14 days.

Exclusion criteria

Exclusion Criteria:

  • Have any form of diabetes other than T2DM.
  • Have to the active substance of LY2963016 or to any of the .
  • Have any disorder, other than T2DM, that in the investigator's opinion, would preclude participation in the trial.
  • Are receiving systemic glucocorticosteroids therapy or have excessive insulin resistance (total insulin dose >2 units per kilogram).
  • Have a history or diagnosis of infection, and C.
  • Have comorbidities of unstable angina, cardiac failure (Stage III or IV as per guidelines) or renal failure (estimated \<30 milliliters/minute/meter squared).
  • Are pregnant or intend to become pregnant during the course of the study; or are sexually active women of not actively practicing by a medically acceptable method as determined by the investigator.
  • Is a woman who is breastfeeding.
  • Have participated within the last 30 days in a clinical trial involving an product other than the LY2963016. If the previous investigational product has a long half-life, 3 months or 5 half-lives (whichever is longer) should have passed.
  • Have previously completed or withdrawn from this study or any other study investigating LY2963016. This exclusion criterion does not apply to participants who are rescreened prior to baseline visit.
  • Are currently enrolled in any other clinical study involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study.
  • Are unwilling or unable to comply with the use of a glucometer.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
304 participants (actual)

Study arms

  • Experimental
    Insulin Glargine

    Participants received insulin glargine once a day (QD) subcutaneously (SC) with a starting dose of 10 units. Participants self-titrated once or twice weekly until fasting blood glucose level was lowered to \<100 milligrams per deciliter (mg/dL). Dose was reduced by 4 units in case of hypoglycemia.

    Drug: Insulin Glargine

Interventions

06

What researchers measure

Primary outcomes

  1. Number or Participants With Hypoglycemic Events

    Hypoglycemic event is when the fasting blood glucose (FBG) level is ≤ 54 milligrams per deciliter (mg/dL) \[≤ 3.0 millimoles per liter (mmol/L)\].

    Time frame: Baseline to Week 24

Secondary outcomes

  1. Basal Insulin Dose

    Basal Insulin Dose at Week 24.

    Time frame: Week 24

  2. Change From Baseline in Body Weight

    Change from baseline in body weight was evaluated. Least Square (LS) mean was calculated using generalized linear model with the analysis variable as outcome, and the baseline of the analysis variable as covariate.

    Time frame: Baseline, Week 24

  3. Change From Baseline in Hemoglobin A1c (HbA1c)

    HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time. LS mean was calculated using generalized linear model with the analysis variable as outcome, and the baseline of analysis variable as covariate.

    Time frame: Baseline, Week 12 and Week 24

  4. Change From Baseline in 7-Point Self-Monitoring Blood Glucose (SMBG) Values

    Seven-point SMBG was completed at the following timepoints: Before Breakfast, 2 Hours After Morning Meal, Before Mid-Day Meal, 2 Hours After Mid-Day Meal, Before Evening Meal, 2 Hours After Evening Meal and at 3 AM (± 1 hour). LS mean was calculated using generalized linear model with the analysis variable as outcome, and the baseline of analysis variable as covariate.

    Time frame: Baseline, Week 24

  5. Change From Week 4 in Insulin Treatment Satisfaction Questionnaire (ITSQ)

    The ITSQ is a 22-item questionnaire that assesses treatment satisfaction for participants taking insulin, under 5 domains: Inconvenience of Regimen \[(IR) - 5 items\], Lifestyle Flexibility \[(LF) - 3 items\], Glycemic Control \[(GC) - 3 items\], Hypoglycemic Control \[(HC) - 5 items\], Insulin Delivery Device \[(IDD) - 6 items\]. Each Item is measured on a 7-point scale, with scores ranging for IR from 5 to 35, LF from 3 to 21, GC from 3 to 21, HC from 5 to 35, IDD from 6 to 42. Lower scores reflect better outcomes. LS mean was calculated using generalized linear model with the analysis variable as outcome, and the baseline of analysis variable as covariate. ITSQ was not evaluated at Week 0. For this outcome, Week 4 was considered as baseline.

    Time frame: Baseline (Week 4), Week 24

07

Results

Posted Feb 15, 2024

Participant flow

Participant flow — Overall Study
MilestoneInsulin Glargine
Started304
Participants who received at least one dose of study drug259
Completed218
Not completed86
Withdrew: Death1
Withdrew: Withdrawal by subject24
Withdrew: Lost to follow-up1
Withdrew: Physician decision1
Withdrew: Due to unavailable glucometer1
Withdrew: Covid 1952
Withdrew: Participant dropped out as required laboratory test was not performed5
Withdrew: Due to low fasting blood sugar levels1

Outcome measures

PrimaryNumber or Participants With Hypoglycemic Events

Hypoglycemic event is when the fasting blood glucose (FBG) level is ≤ 54 milligrams per deciliter (mg/dL) \[≤ 3.0 millimoles per liter (mmol/L)\].

Time frame:
Baseline to Week 24
Reported as:
Number · participants
Number or Participants With Hypoglycemic Events
participantsInsulin Glargine
Number or Participants With Hypoglycemic Events10
SecondaryBasal Insulin Dose

Basal Insulin Dose at Week 24.

Time frame:
Week 24
Reported as:
Mean · Units per kilograms per day (U/kg/day)
Basal Insulin Dose
Units per kilograms per day (U/kg/day)Insulin Glargine
Basal Insulin Dose0.30 ± 0.116
SecondaryChange From Baseline in Body Weight

Change from baseline in body weight was evaluated. Least Square (LS) mean was calculated using generalized linear model with the analysis variable as outcome, and the baseline of the analysis variable as covariate.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · kilogram (kg)
Change From Baseline in Body Weight
kilogram (kg)Insulin Glargine
Change From Baseline in Body Weight-0.5 ± 0.15
SecondaryChange From Baseline in Hemoglobin A1c (HbA1c)

HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time. LS mean was calculated using generalized linear model with the analysis variable as outcome, and the baseline of analysis variable as covariate.

Time frame:
Baseline, Week 12 and Week 24
Reported as:
Least squares mean · Percentage of HbA1c
Change From Baseline in Hemoglobin A1c (HbA1c)
Percentage of HbA1cInsulin Glargine
At Week 12-0.641 ± 0.0719
At Week 24-0.860 ± 0.0847
SecondaryChange From Baseline in 7-Point Self-Monitoring Blood Glucose (SMBG) Values

Seven-point SMBG was completed at the following timepoints: Before Breakfast, 2 Hours After Morning Meal, Before Mid-Day Meal, 2 Hours After Mid-Day Meal, Before Evening Meal, 2 Hours After Evening Meal and at 3 AM (± 1 hour). LS mean was calculated using generalized linear model with the analysis variable as outcome, and the baseline of analysis variable as covariate.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · milligrams per deciliter (mg/dL)
Change From Baseline in 7-Point Self-Monitoring Blood Glucose (SMBG) Values
milligrams per deciliter (mg/dL)Insulin Glargine
Blood glucose concentration before breakfast-38.7 ± 2.12
Blood glucose concentration 2 hours after morning meal-54.3 ± 2.87
Blood glucose concentration before midday meal-32.9 ± 2.52
Blood glucose concentration 2 hours after midday meal-43.6 ± 2.98
Blood glucose concentration before evening meal-29.4 ± 2.41
Blood glucose concentration 2 hours after evening meal-45.7 ± 2.97
Blood glucose concentration at 3AM (± 1 hour)-32.9 ± 2.20
SecondaryChange From Week 4 in Insulin Treatment Satisfaction Questionnaire (ITSQ)

The ITSQ is a 22-item questionnaire that assesses treatment satisfaction for participants taking insulin, under 5 domains: Inconvenience of Regimen \[(IR) - 5 items\], Lifestyle Flexibility \[(LF) - 3 items\], Glycemic Control \[(GC) - 3 items\], Hypoglycemic Control \[(HC) - 5 items\], Insulin Delivery Device \[(IDD) - 6 items\]. Each Item is measured on a 7-point scale, with scores ranging for IR from 5 to 35, LF from 3 to 21, GC from 3 to 21, HC from 5 to 35, IDD from 6 to 42. Lower scores reflect better outcomes. LS mean was calculated using generalized linear model with the analysis variable as outcome, and the baseline of analysis variable as covariate. ITSQ was not evaluated at Week 0. For this outcome, Week 4 was considered as baseline.

Time frame:
Baseline (Week 4), Week 24
Reported as:
Least squares mean · score on a scale
Change From Week 4 in Insulin Treatment Satisfaction Questionnaire (ITSQ)
score on a scaleInsulin Glargine
ITSQ IR Score-0.3 ± 0.04
ITSQ LF Score-0.3 ± 0.05
ITSQ GC Score-0.2 ± 0.05
ITSQ HC Score-0.3 ± 0.05
ITSQ IDD Score-0.3 ± 0.04

Adverse events

Collected over Up to 28 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Insulin Glargine1/259 (0.4%)1/259 (0.4%)8/259 (3.1%)
Most frequent serious events
Most frequent serious events
EventInsulin Glargine
DeathGeneral disorders1/259
Most frequent other events
Most frequent other events
EventInsulin Glargine
AnaemiaBlood and lymphatic system disorders5/259
PyrexiaGeneral disorders1/259
Urinary tract infectionInfections and infestations1/259
HyperglycaemiaMetabolism and nutrition disorders1/259
CoughRespiratory, thoracic and mediastinal disorders1/259

Baseline characteristics

All participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)Insulin Glargine
Mean52.1 ± 11.38
Sex: Female, Male
Sex: Female, Male(Participants)Insulin Glargine
Female93
Male166
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Insulin Glargine
American Indian or Alaska Native0
Asian259
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)Insulin Glargine
India259
08

Study locations

11 sites
  • Sir Ganga Ram Hospital
    New Delhi, Delhi 110060, India
  • DIACARE
    Ahemdabad, Gujarat 380015, India
  • Gujarat Endocrine Center
    Ahmedabad, Gujarat 380006, India
  • Nirmal Hospital Private Limited
    Surat, Gujarat 395002, India
  • Government Medical College & Sir Sayajirao General Hospital
    Vadodara, Gujarat 390001, India
  • Sumandeep Vidhyapeeth & Dhiraj General Hospital
    Vadodara, Gujarat 391760, India
  • Bangalore Diabetes Center
    Bangalore, Karnataka 560043, India
  • Supe Heart & Diabetes Hospital & Research Centre
    Nasik, Maharashtra 422002, India
  • GSVM Medical College
    Kanpur, Uttar Pradesh 208002, India
  • Popular Hospital
    Varanasi, Uttar Pradesh 221004, India
  • Maharaja Agrasen Hospital
    New Delhi, 110026, India
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2019 to primary completion in Jul 2021, 19 months.

Results were first posted in Feb 2024, 2 years 6 months after primary completion.

Of 132 industry-sponsored phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 28. This study's 19 months is close to that.

Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2019
First posted
Nov 6, 2019
StartActual
Dec 16, 2019
Primary completionActual
Jul 30, 2021
CompletionActual
Jul 30, 2021
Results first posted
Feb 15, 2024
Last update
Feb 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04153981
Responsible party
Sponsor
First posted
Nov 6, 2019
Start date
Dec 16, 2019
Primary completion
Jul 30, 2021
Completion
Jul 30, 2021
Results posted
Feb 15, 2024
Last update
Feb 15, 2024

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin Glargine

Start the discussion